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Aim: An inverse relationship between coffee consumption and mortality has been
reported in the general population. However, the effect of coffee consumption in diabetes
remains unclear. We aimed to evaluate the association of caffeine consumption and
caffeine source with mortality among patients with diabetes.
Methods: We examined the association of caffeine consumption with mortality among
1974 women and 1974 men with diabetes, using the National Health and Nutrition
Examination Survey (NHANES) 1999–2010. Caffeine consumption was assessed at
baseline using 24 h dietary recalls. Cox proportional hazardmodels were fitted to estimate
hazard ratios (HR) for all-cause, cardiovascular, and cancer-related mortality according
to caffeine consumption and its source, adjusting for potential confounders.
Results: A dose-dependent inverse association between caffeine and all-cause
mortality was observed in women with diabetes. Adjusted HR for death among women
who consumed caffeine, as compared with non-consumers, were: 0.57 (95% CI,
0.40–0.82) for <100mg of caffeine/day, 0.50 (95% CI, 0.32–0.78) for 100 to <200mg
of caffeine/day, and 0.39 (95% CI, 0.23–0.64) for ≥200mg of caffeine/day (p = 0.005
for trend). This association was not observed in men. There was a significant interaction
between sex and caffeine consumption (p = 0.015). No significant association between
total caffeine consumption and cardiovascular or cancer mortality was observed. Women
who consumed more caffeine from coffee had reduced risk of all-cause mortality
(p = 0.004 for trend).
Conclusion: Our study showed a dose-dependent protective effect of caffeine
consumption on mortality among women with diabetes.
Keywords: caffeine, coffee, mortality, diabetes, national health and nutrition examination survey
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INTRODUCTION
Diabetes is a major public health problem with an increasing
prevalence worldwide (1). Given its significant burden, it is
important to identify lifestyle factors for improvement of
prognosis. Caffeine is provided in different sources, mainly
coffee, tea, and soft drinks. Coffee contains more caffeine
than the majority of foods and constitutes one of the most
commonly consumed beverages worldwide. The detection of a
health-related effect associated with coffee consumption may
have a potential great impact in public health (2). Coffee
has been referred as containing several bioactive compounds
including antioxidants with potentially beneficial properties.
An inverse association between coffee consumption and serum
biomarkers of inflammation and insulin resistance has been
described (3–5). A meta-analysis of prospective studies (6)
and a systematic review (7) showed that coffee consumption
might be associated with reduction in the incidence of type 2
diabetes.
A recent dose-response systematic review concluded that
coffee consumption was strongly associated with a risk reduction
in all-cause and cardiovascular disease (CVD) mortality.
However, this systematic review excluded studies which analyzed
specific subpopulations, such as those including only people
with diabetes (8). Although caffeine consumption appears to be
associated with a decreased risk of developing type 2 diabetes,
it is unclear if its protective effect persists in people with
established diabetes. In a prospective study including 4,365
patients with a prior myocardial infarction, drinking coffee
was associated with lower risk of cardiovascular mortality and
ischemic heart disease mortality (9). In this study, significant
inverse associations were reported in patients without diabetes,
whereas the associations were weak and non-significant in the
smaller group with diabetes.
After reviewing the literature, we found only three studies
specific of patients with diabetes. One prospective cohort of
7,170 female registered nurses with diabetes found that habitual
coffee consumption was not associated with increased risk
for cardiovascular diseases or premature mortality (10). A
similar cohort of 3,497 male health professionals with diabetes
found no association between caffeine consumption and CVD
or all-cause mortality (11). Another study, restricted to a
Finnish population (3,837 patients), found that in patients
with type 2 diabetes, coffee drinking was associated with
reduced all-cause, CVD, and coronary heart disease mortality
(12). However, in this study, no adjustments were made
for diabetes duration, complications of diabetes, and insulin
treatment.
Considering that there is limited and conflicting evidence
regarding the relationship between caffeine consumption
and mortality in people with diabetes, we examined the
continuous National Health and Nutrition Examination
Survey (NHANES) 1999–2010 database to evaluate the effect
of caffeine consumption and caffeine source on all-cause,
cardiovascular, and cancer mortality among patients with
diabetes.
MATERIALS AND METHODS
Study Design and Participants
We performed an analysis of the continuous NHANES database.
The NHANES is a periodic survey conducted by the National
Center for Health Statistics (NCHS) of the Centers for Disease
Control and Prevention (CDC). NHANES is a stratified, multi-
stage survey using a nationally representative sample of the
non-institutionalized civilian population of the United States.
Participants are selected at random through a complex statistical
process each year, and they complete personal structured
interviews at home and then perform a physical examination
at a mobile examination center that includes height, weight,
and laboratory measurements (13). We used data from 1999 to
2010, that includes 62,160 people. We restricted our analysis
to individuals with ≥18-year-old (35,379 subjects) and with
diabetes (4,544 subjects). Diabetes was defined by a self-reported
previous diagnosis, a hemoglobin A1c level of≥6.5%, or a fasting
plasma glucose level of ≥126 mg/dL. Both patients with type 1
and type 2 diabetes were included. We excluded 596 subjects
due to implausible alimentary reports (as defined in previous
studies: consumption of <500 kcal/day or >3500 kcal/day)
(14) or missing information on caffeine consumption and/or
mortality. Finally, 3,948 subjects were included in our present
analysis. The NCHS Research Ethics Review Board reviewed
and approved NHANES, and all participants provided written
informed consent. This study was registered at www.clinicaltrials.
gov as NCT03367806.
Assessment of Exposure
In all cycles of NHANES 1999–2010, a 24-h dietary recall
was collected. Using an automated multiple-pass method, all
food items and quantities consumed in the 24 h preceding
the interview were recorded. For participants in the 1999–
2002 NHANES, only one in-person 24-h dietary recall was
administered. The cycles starting from 2003 onward included two
recalls, the first one in-person and the second one via telephone
collected 3 to 10 days following the first dietary interview but not
on the same day of the week. To calculate the caffeine, energy,
and nutrient intakes, for participants in the 1999–2002NHANES,
we used the nutritional information from foods and beverages
collected in the single 24-h dietary recall. For participants in the
2003-2010 NHANES, the mean of the nutritional information
from both recalls was used (15). NHANES includes information
regarding nutrient source by type of food ingested. This data was
used to ascertain the quantity of ingested caffeine originating in
coffee, tea, or soft drink for each patient. The impact of caffeine
consumption obtained from each of the three types of drink on
different outcomes was evaluated.
Considering the mean caffeine content per unit of caffeinated
beverage (95mg in 8 oz. of coffee, 48mg in 8 oz. of tea, and 30mg
in 12 oz. of cola) (16), we divided the daily intake of caffeine
from all sources and from coffee into three categories (<100mg,
100 to <200mg, and 200mg or more). Given the low number of
patients with caffeine intake from tea and from soft drinks, and
the high variability of caffeine in these beverages, those patients
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were divided into tertiles of consumption and are presented as
Supplementary Material.
Continuous variables are presented as means with standard
deviations except for polyunsaturated to saturated fatty acids
ratio, fibers per day, and years of diabetes which were
summarized using median (interquartile range) due to their
right-skewed distributions. Categorical variables are presented as
percent with 95% confidence intervals.
Outcomes
The primary outcome was time to death. As secondary outcomes,
we selected time to cardiovascular death and time to death by
TABLE 1 | Baseline characteristics of the study population.










P-value* P for trend
Age, years 58.3 (15.8) 61.6 (15.0) 0.022 59.5 (14.3) 0.469 58.6 (13.2) 0.829 0.041
Non-Hispanic White, % 34.7% 53.0% 0.001 59.2% <0.001 79.2% <0.001 <0.001
Annual family income <$25000, % 51.4% 48.8% 0.399 39.1% 0.018 38.6% 0.010 0.004
Education level -Less than 9th grade, % 22.0% 15.9% 0.119 10.1% 0.002 9.1% <0.001 <0.001
Current smokers, % 6.3% 8.4% 0.312 12.7% 0.029 25.9% <0.001 <0.001
Former smokers, % 24.0% 26.5% 0.548 34.3% 0.053 33.2% 0.079 0.023
Alcohol consumption >20 grams/day, % 2.3% 2.9% 0.651 5.2% 0.172 4.9% 0.219 0.126
Carbohydrates per day, gram/100 kcal 12.9 (3.0) 12.7 (2.3) 0.448 12.1 (2.3) 0.020 11.8 (2.5) 0.001 <0.001
Polyunsaturated/saturated fatty acids ratio 0.73 (0.52–1.11) 0.70 (0.50–0.94) 0.061 0.67 (0.49–0.92) 0.056 0.65 (0.49–0.84) 0.001 0.001
Fiber per day, gram/100 kcal 0.95 (0.54–1.27) 0.91 (0.65–1.16) 0.957 0.85 (0.64–1.09) 0.107 0.78 (0.59–1.03) 0.045 0.002
Low physical activity level, % 44.9% 37.2% 0.109 37.4% 0.201 41.9% 0.607 0.469
BMI, kg/m2 34.7 (8.9) 33.2 (8.3) 0.083 33.0 (6.9) 0.034 33.8 (7.8) 0.342 0.775
Hypertension, % 67.3% 67.2% 0.978 72.5% 0.266 67.0% 0.957 0.889
Dyslipidemia, % 53.1% 60.3% 0.188 61.3% 0.128 58.7% 0.283 0.926
Time since diagnosis of diabetes, years 3 (0–13) 5 (0–12) 0.100 5 (1–13) 0.415 7 (1–15) 0.092 0.592
Diabetic retinopathy, % 24.0% 21.7% 0.591 22.0% 0.722 25.4% 0.661 0.219
Diabetic kidney disease, % 23.2% 26.4% 0.511 27.8% 0.477 16.8% 0.100 0.005
Macrovascular complications, % 19.3% 18.1% 0.696 19.2% 0.988 19.5% 0.908 0.629
Insulin treatment, % 21.5% 18.6% 0.465 21.0% 0.876 27.6% 0.274 0.021










P-value* P for trend
Age, years 57.3 (14.6) 60.0 (14.0) 0.080 58.0 (14.0) 0.660 58.1 (12.4) 0.601 0.245
Non-Hispanic White, % 41.4% 54.3% 0.013 70.4% <0.001 80.3% <0.001 <0.001
Annual family income <$25000, % 35.2% 34.7% 0.871 27.6% 0.110 27.9% 0.123 0.029
Education level - Less than 9th grade, % 18.2% 16.3% 0.616 12.6% 0.126 10.2% 0.020 0.001
Current smokers, % 16.0% 11.8% 0.300 14.8% 0.826 25.7% 0.097 <0.001
Former smokers, % 39.7% 45.4% 0.247 46.7% 0.199 45.1% 0.366 0.834
Alcohol consumption >20 grams/day, % 15.9% 9.8% 0.073 11.4% 0.302 11.6% 0.169 0.867
Carbohydrates per day, gram/100 kcal 11.9 (3.1) 11.8 (2.5) 0.958 11.7 (2.4) 0.573 11.3 (2.6) 0.124 0.006
Polyunsaturated/saturated fatty acids ratio 0.70 (0.47–0.98) 0.68 (0.48–0.91) 0.306 0.70 (0.50–0.91) 0.249 0.64 (0.47–0.88) 0.133 0.216
Fiber per day, gram/100 kcal 0.83 (0.55–1.10) 0.83 (0.61–1.14) 0.624 0.76 (0.55–1.09) 0.444 0.78 (0.57–0.99) 0.134 0.010
Low physical activity level, % 40.9% 30.0% 0.030 32.8% 0.157 33.4% 0.120 0.773
BMI, kg/m2 31.9 (8.1) 31.2 (6.1) 0.481 31.4 (6.0) 0.601 32.4 (7.3) 0.661 0.102
Hypertension, % 66.7% 60.5% 0.239 60.1% 0.278 55.1% 0.046 0.062
Dyslipidemia, % 55.6% 58.2% 0.666 60.0% 0.486 63.0% 0.207 0.166
Time since diagnosis of diabetes, years 3 (0–11) 4 (0–11) 0.882 3 (0–10) 0.539 5 (0–12) 0.966 0.779
Diabetic retinopathy, % 26.4% 26.1% 0.932 18.3% 0.223 18.6% 0.432 0.198
Diabetic kidney disease, % 15.1% 25.0% 0.010 16.9% 0.639 20.1% 0.197 0.408
Macrovascular complications, % 23.2% 24.8% 0.662 20.5% 0.551 26.2% 0.448 0.378
Insulin treatment, % 20.9% 21.8% 0.814 21.6% 0.888 23.2% 0.614 0.563
Baseline population characteristics according to caffeine consumption among women and men. * vs no consumption group. Kcal, kilocalorie; BMI, Body mass index. Significant P for
trend values are shown in bold.
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cancer. Mortality status and cause of death were determined
by NHANES linked National Death Index public-access files
through December 31, 2011.
Statistical Analysis
All calculations took into account the complex survey design of
the NHANES dataset and were analyzed according to the CDC
analytic recommendations (17).
To assess the crude association between caffeine consumption
and time to death, we performed a Kaplan-Meier curve and
log-rank test. We performed further analysis using the Cox
proportional hazards models to adjust for potential confounders.
We built two different Cox Proportional Hazard models to
analyze the primary outcome: one model including age at
baseline, race (Mexican American, other Hispanic, non-Hispanic
white, non-Hispanic black, other race), annual family income
(<$25000, $25000 to $75000, >$75000), smoking status (never
smoker, current smoker, or former smoker), and diabetic
nephropathy (glomerular filtration rate <60 mL/min/1.73 m2 or
urine albumin/creatinine ratio ≥300 mg/g) (model 1); Model 2
including all model 1 covariates plus body mass index (BMI)
(<20.0, 20.0 to <25.0, 25.0 to <30.0, 30.0 to <35.0, 35.0 to
<40.0,≥40.0 kg/m2), education level [less than 9th grade, 9-11th
grade, high-school grade, some college or associate’s (AA) degree,
college graduate and above], daily carbohydrate consumption
(grams of carbohydrate per 100 kcal), alcohol consumption
(no alcohol consumption, <20 grams/day, ≥20 grams/day),
years since diabetes diagnosis (undiagnosed, ≤5 years, 5 to
≤15 years, >15 years), diagnosis of hypertension, retinopathy,
macrovascular complications (coronary artery disease, history of
myocardial infarction, or history of stroke), insulin treatment
and survey cycle (years 1999–2000, 2001–2002, 2003–2004,
2005–2006, 2007–2008, or 2009–2010). Regarding cause-specific
mortality, we only used themore restrictive model (model 1), due
to the low number of outcome events. We tested for interactions
between caffeine consumption and the other 14 variables in
model 2 for all-cause mortality.
We also considered physical activity as an important potential
confounder. Physical activity was measured differently along the
various NHANES cycles. Therefore, we chose to use variables
that allowed categorization of physical activity level into three
categories (low, intermediate, and high), to combine them into a
single variable. From 1999 to 2006 the physical activity level was
assessed with the question “compare activity with others of the
same age” (participants were classified into approximate tertiles
as low if “less active,” as intermediate if “about the same,” and
as high if “more active,” with 31, 28, and 41% of participants,
respectively, falling into these categories). From 2007 to 2010 the
weekly metabolic equivalents (MET) minutes of physical activity
(accounting for vigorous work-related activity, moderate work-
related activity, walking or bicycling for transportation, vigorous
leisure-time physical activity, and moderate leisure-time physical
activity) was divided into tertiles (participants were classified as
low if included in the lower MET-minute tertile, as intermediate
if in the middle MET-minute tertile, and as high if in the higher
MET-minute tertile). The results of mortality associated with
caffeine consumption adjusted for physical activity are presented
in the Supplementary Material.
As sensitivity analysis, we additionally performed the Cox
proportional hazards models using daily intake of caffeine (from
all sources and from coffee, tea, or soft drinks) as a continuous
variable.
Multiple imputation by chained equations was used for
dealing with missing data regarding covariates. Twenty
imputations per missing observation were performed and
analyzed. A test for trend over increasing caffeine consumption
categories was performed where each category median was
modeled as a continuous variable in the regression. A two-sided
p-value of<0.05 was considered statistically significant. Analyses
were performed with Stata (version 14.2).
RESULTS
Association of Caffeine Consumption With
Dietary and Lifestyle Factors
Caffeine consumption at baseline was associated with several
other dietary and lifestyle factors, with some differences
according to sex (Table 1). In both men and women, compared
with people who did not drink caffeine-containing beverages,
caffeine consumers were more likely to be non-Hispanic white
and current smokers, to have a higher level of education, to have
an annual family income higher than $25000, and to consume less
carbohydrates and less fibers per kilocalorie ingested. Women
that consumed caffeine were more likely to be treated with
insulin, had less diabetic kidney disease, and a lower ratio of
polyunsaturated/saturated fatty acids intake.
Caffeine Consumption and Mortality
During a median 57 months of follow-up (total person-years,
21,606), 407 men and 351 women died. There was a significant
interaction between sex and caffeine consumption with respect
to mortality (p = 0.015 for interaction in model 2). In
the unadjusted analysis (Figure 1), and also after multivariate
analysis, caffeine consumption was associated with a decrease
in all-cause mortality in women (p = 0.005 for trend across
FIGURE 1 | Kaplan-Meier curves for all-cause mortality by caffeine
consumption among women.
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categories, in model 2). A dose-dependent inverse association
between caffeine and all-cause mortality was observed. Hazard
ratios (HR) for death among women who consumed caffeine, as
compared with women who did not consume caffeine, were as
follows: 0.57 (95% confidence interval [CI], 0.40 to 0.82) for less
than 100mg of caffeine per day, 0.50 (95% CI, 0.32 to 0.78) for
100 to less than 200mg of caffeine, and 0.39 (95%CI, 0.23 to 0.64)
for 200mg or more of caffeine per day (Table 2). In contrast, this
association was not observed among men (Figure 2), even after
adjustment for potential confounders (Table 2).
Specific causes of death were also examined. There were 199
deaths from CVD and 133 deaths due to cancer during the
follow-up. After multivariate adjustment, there was no significant
association between caffeine consumption and deaths from CVD
or cancer, both in men and women (Table 2).
Source of Caffeine Consumption and
Mortality
An analysis of caffeine consumption according to its origin on
coffee, tea, or soft drinks was also performed. In the unadjusted
analysis, and also after multivariate analysis, a reduced risk in
all-cause mortality was observed in women with diabetes who
consumed caffeine from coffee (Table 3). The adjusted hazard
ratios were as follows: 0.74 (95% CI, 0.53 to 1.02) for less than
100mg of caffeine per day, 0.71 (95% CI, 0.46 to 1.09) for 100mg
TABLE 2 | Association of caffeine consumption with mortality.















No. of deaths (%) 59 (26.9%) 170 (17.4%) 73 (16.7%) 49 (14.5%) 351 (17.8%)
Unadjusted HR – 0.71 (0.51–1.00) 0.63 (0.42–0.96) 0.46 (0.27–0.78) 0.010 0.86 (0.76–0.96)
Model 1 HR – 0.60 (0.43–0.83) 0.52 (0.34–0.80) 0.42 (0.25–0.71) 0.020 0.88 (0.77–0.99)
Model 2 HR – 0.57 (0.40–0.82) 0.50 (0.32–0.78) 0.39 (0.23–0.64) 0.005 0.86 (0.76–0.96)
CVD mortality
No. of deaths (%) 16 (7.3%) 40 (4.1%) 15 (3.4%) 8 (2.4%) 79 (4.0%)
Unadjusted HR – 0.66 (0.33–1.30) 0.45 (0.22–0.93) 0.40 (0.15–1.08) 0.118 0.82 (0.68–0.99)
Model 1 HR – 0.52 (0.26–1.02) 0.37 (0.18–0.76) 0.38 (0.14–1.00) 0.208 0.86 (0.70–1.06)
Cancer mortality
No. of deaths (%) 9 (4.1%) 26 (2.7%) 11 (2.5%) 8 (2.4%) 54 (2.7%)
Unadjusted HR – 0.87 (0.34–2.22) 0.70 (0.24–2.02) 0.49 (0.13–1.80) 0.204 0.88 (0.65–1.19)
Model 1 HR – 0.71 (0.27–1.89) 0.52 (0.17–1.59) 0.35 (0.08–1.53) 0.126 0.84 (0.59–1.20)















No. of deaths (%) 50 (26.9%) 159 (21.5%) 82 (17.5%) 116 (20.0%) 407 (20.6%)
Unadjusted HR – 1.24 (0.81–1.91) 1.00 (0.64–1.57) 1.21 (0.81–1.82) 0.739 1.03 (0.97–1.09)
Model 1 HR – 0.94 (0.62–1.41) 0.77 (0.49–1.23) 0.91 (0.60–1.39) 0.925 1.04 (0.98–1.10)
Model 2 HR – 1.09 (0.70–1.69) 0.90 (0.55–1.47) 1.01 (0.65–1.56) 0.783 1.03 (0.97–1.10)
CVD mortality
No. of deaths (%) 11 (5.9%) 50 (6.8%) 23 (4.9%) 36 (6.2%) 120 (6.1%)
Unadjusted HR – 2.09 (0.99–4.39) 1.59 (0.58–4.33) 1.92 (0.85–4.31) 0.749 1.07 (0.98–1.18)
Model 1 HR – 1.47 (0.70–3.12) 1.13 (0.41–3.10) 1.18 (0.54–2.58) 0.517 1.07 (0.98–1.16)
Cancer mortality
No. of deaths (%) 12 (6.5%) 28 (3.8%) 18 (3.8%) 21 (3.6%) 79 (4.0%)
Unadjusted HR – 1.15 (0.51–2.63) 0.96 (0.37–2.47) 1.17 (0.52–2.62) 0.830 1.09 (0.97–1.22)
Model 1 HR – 1.03 (0.42–2.54) 0.78 (0.28–2.13) 0.90 (0.37–2.18) 0.777 1.07 (0.95–1.22)
Model 1: Adjusted for age, race, annual family income, smoking status, and diabetic kidney disease. Model 2: Adjusted for covariates in Model 1 and body mass index, education
level, daily carbohydrate consumption, alcohol consumption, years since diabetes diagnosis, diagnosis of hypertension, retinopathy, macrovascular complications, insulin treatment and
survey cycle.
aHR for the continuous analysis are presented for each 100mg increase in caffeine consumption. HR, Hazard Ratio; CVD, Cardiovascular disease. Significant P for trend values and
significant hazard ratios in the continuous analysis are shown in bold.
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FIGURE 2 | Kaplan-Meier curves for all-cause mortality by caffeine
consumption among men.
to less than 200mg of caffeine, and 0.53 (95% CI, 0.35 to 0.80) for
200mg or more of caffeine per day (p = 0.004 for trend across
categories, in model 2). There were no significant associations of
caffeine consumption from coffee with cardiovascular or cancer
mortality.
Regarding caffeine consumption from tea and from soft
drinks, there were no significant associations with all-cause or
cause-specific mortality (Supplementary Tables 1,2).
Among men, there were no significant associations
between source of caffeine and mortality (Table 3,
Supplementary Table 2).
Sensitivity Analysis
The analysis of the association between source of caffeine and
mortality using daily intake of caffeine as a continuous variable
showed similar results (Table 2, Supplementary Table 3).
Among women, the HR for each 100mg increase in caffeine
consumption for all-cause mortality was 0.86 (95% CI,
0.76–0.96; p = 0.009) for unadjusted analysis and 0.86
(95% CI, 0.76–0.96; p = 0.011) for adjusted analysis. The
effect of caffeine consumption according to caffeine source
on all-cause, cardiovascular, and cancer mortality among
women and men were also concordant with the main
analysis (Table 2, Supplementary Table 3). Furthermore,
the association of caffeine consumption with mortality adjusting
for physical activity was also consistent with our main analysis
(Supplementary Table 4).
DISCUSSION
Our study showed a dose-dependent protective effect of
caffeine consumption on all-cause mortality among women
with diabetes. There was no significant association between
caffeine consumption and mortality among men with diabetes.
Although caffeine consumption in women was associated with
lower all-cause mortality, no association was found between
caffeine consumption and cardiovascular or cancer mortality.
When comparing caffeine consumption according to its origin on
coffee, tea, or soft drinks, women with diabetes who consumed
more caffeine from coffee also had reduced risk of all-cause
death. No differences on mortality were observed on the adjusted
analysis for consumption of caffeine from tea or soft drinks.
However, these results should be interpreted cautiously as the
number of events in each source of caffeine category was low.
Previous studies had already shown a protective effect of
coffee consumption in the general population. Loftfield et al.,
for example, showed a decreased risk of all-cause mortality in
people with higher coffee consumption (18). Specifically, an
inverse association was found between coffee consumption and
diabetes-related death. In the subgroup of participants with self-
reported diabetes, this association seemed stronger. Regarding
studies in people with diabetes, a study in the Finnish population
in 3,837 patients, found an inverse relationship between coffee
drinking and all-cause and cardiovascular-associated mortality
(12). On the other hand, two previous studies have obtained
neutral results in patients of both sexes. In a study including
only female nurses with diabetes, habitual coffee consumption
was not associated with cardiovascular diseases or premature
mortality (10). Furthermore, no significant association between
coffee consumption and mortality was observed in a prospective
cohort of male health professionals with diabetes (11). Although
the Finnish population study results are not consistent with
these two studies, their results also suggest a protective effect of
caffeine-containing beverages as observed in our study. Possible
explanations for these differences between studies might be the
use of different endpoints, different duration of follow-up and
differences in the population’s characteristics.
Our results suggest that biological differences may
exist between men and women regarding the effects of
caffeine consumption. Considering the pathophysiology and
complications of diabetes, several studies have highlighted
differences between sexes (19). Genetic and epigenetic
mechanisms, nutritional factors, and sedentary lifestyle
have been shown to differently affect diabetes complications
according to sex (19). Furthermore, caffeine may induce different
hemodynamic effects in men and women. In a double-blind
trial comparing age-matched women and men, women showed
an increase in cardiac output, whereas men showed increased
vascular resistance after a dietary dose of caffeine (20). These
differences may partially explain why caffeine intake is associated
with reduced mortality in women with diabetes whereas the
effects in mortality are neutral in men with diabetes. In the
general population, some studies have also suggested differences
in the response to coffee between sexes. The inverse association
of coffee drinking with total mortality has been shown to be
reduced in men comparing to women (21–23).
The direction and strength of the association between caffeine
consumption and mortality has varied between studies in the
general population. In a study including Japanese participants
without a history of cancer, myocardial infarction, or stroke
at baseline, coffee consumption was strongly associated with
reduced all-cause and cardiovascular mortality among women
[HR of 0.48 (0.29–0.80) for 1–2 cups of coffee per day and
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TABLE 3 | Association of caffeine consumption from coffee with mortality.













No. of deaths (%) 127 (17.3%) 130 (18.4%) 58 (18.4%) 36 (16.6%) 351 (17.8%)
Unadjusted HR – 1.25 (0.94–1.66) 1.09 (0.75–1.60) 0.73 (0.50–1.09) 0.077 0.91 (0.83–0.99)
Model 1 HR – 0.79 (0.60–1.04) 0.74 (0.47–1.15) 0.57 (0.38–0.85) 0.009 0.87 (0.78–0.98)
Model 2 HR – 0.74 (0.53–1.02) 0.71 (0.46–1.09) 0.53 (0.35–0.80) 0.004 0.85 (0.76–0.95)
CVD mortality
No. of deaths (%) 31 (4.2%) 32 (4.5%) 11 (3.5%) 5 (2.3%) 79 (4.0%)
Unadjusted HR – 1.51 (0.86–2.66) 0.98 (0.42–2.26) 0.50 (0.18–1.41) 0.123 0.83 (0.69–0.99)
Model 1 HR – 0.96 (0.56–1.66) 0.72 (0.28–1.85) 0.42 (0.14–1.25) 0.110 0.81 (0.64–1.02)
Cancer mortality
No. of deaths (%) 19 (2.6%) 18 (2.6%) 12 (3.8%) 5 (2.3%) 54 (2.7%)
Unadjusted HR – 1.66 (0.80–3.42) 1.81 (0.74–4.38) 0.89 (0.23–3.41) 0.905 0.99 (0.76–1.29)
Model 1 HR – 1.16 (0.54–2.48) 1.24 (0.47–3.23) 0.59 (0.15–2.39) 0.392 0.91 (0.64–1.29)














No. of deaths (%) 132 (20.1%) 126 (22.0%) 70 (19.6%) 79 (20.4%) 407 (20.6%)
Unadjusted HR – 1.59 (1.19–2.13) 1.13 (0.77–1.66) 1.42 (0.93–2.08) 0.282 1.06 (1.00–1.12)
Model 1 HR – 1.05 (0.76–1.45) 0.80 (0.57–1.11) 1.07 (0.74–1.55) 0.922 1.03 (0.96–1.11)
Model 2 HR – 1.04 (0.74–1.47) 0.76 (0.53–1.08) 1.09 (0.76–1.56) 0.873 1.03 (0.96–1.11)
CVD mortality
No. of deaths (%) 34 (5.2%) 45 (7.9%) 18 (5.0%) 23 (5.9%) 120 (6.1%)
Unadjusted HR – 2.13 (1.35–3.38) 1.15 (0.55–2.42) 1.48 (0.64–3.40) 0.791 1.09 (0.99–1.20)
Model 1 HR – 1.33 (0.79–2.26) 0.70 (0.35–1.41) 0.97 (0.44–2.15) 0.563 1.06 (0.94–1.19)
Cancer mortality
No. of deaths (%) 17 (3.5%) 23 (3.5%) 19 (5.3%) 14 (3.6%) 79 (4.0%)
Unadjusted HR – 3.34 (1.58–7.05) 2.85 (1.39–5.84) 3.12 (1.79–5.42) 0.022 1.09 (1.00–1.19)
Model 1 HR – 2.51 (1.10–5.71) 2.19 (1.00–4.81) 2.24 (1.10–4.56) 0.270 1.06 (0.93–1.20)
Model 1: Adjusted for age, race, annual family income, smoking status, and diabetic kidney disease. Model 2: Adjusted for covariates in Model 1 and body mass index, education level,
daily carbohydrate consumption, alcohol consumption, years since diabetes diagnosis, diagnosis of hypertension, retinopathy, macrovascular complications, insulin treatment, and
survey cycle. aHR for the continuous analysis are presented for each 100mg increase in caffeine consumption from coffee. HR, Hazard Ratio; CVD, Cardiovascular disease. Significant
P for trend values and significant hazard ratios in the continuous analysis are shown in bold.
0.45 (0.20–1.03) for 3 or more cups per day comparing with
no consumption) but not in men (24). Other studies have also
shown inverse associations between consumption of caffeine-
containing beverages and mortality among women, albeit with
weaker associations (22, 25). Although some studies suggest
greater benefits of consumption of caffeine or coffee among
women, these findings are not consistent across studies. Several
studies have shown similar inverse associations between coffee
consumption andmortality in women andmen (26–28). The type
of caffeine-containing beverage, the population’s risk factors or
the duration of follow-up may explain the differences between
studies.
The benefits of coffee may be directly related to caffeine
or to other components present in coffee, including minerals,
phytochemicals, and antioxidants (25, 29). The antioxidant
capacity of these drinks may contribute to the health-protective
effect described with decaffeinated coffee consumption (7). The
lack of significant differences on mortality regarding caffeine
consumption from tea on our study may be explained by
insufficient power. A recent meta-analysis found a significant
association between tea consumption and reduction of all-cause
mortality; furthermore, black tea was inversely associated with
cancer mortality (30).
Tsujimoto et al. also used NHANES data to evaluate the effects
of caffeine consumption in the general population (31). In their
main analysis, caffeine intake was associated with a decreased risk
of all-cause mortality. Although it was not their main objective,
the authors also performed an additional analysis limited to the
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participants with diabetes. Contrary to our results, they reported
a non-significant association between caffeine consumption and
mortality among participants with diabetes. In the study by
Tsujimoto et al., no adjustments were made for diabetes-specific
parameters, including diabetes duration, type of treatment and
complications of diabetes. Participants with diabetes were not
stratified according to sex and no adjustment was performed
for the presence of kidney disease. Furthermore, in the study
by Tsujimoto et al., participants with missing information
on any other potential confounders were excluded, whereas
we included these patients using multiple imputation. The
differences in participants’ selection and in the statistical analyses
techniques used probably account for the differences between
the studies.
Our study has several strengths, including the evaluation of
a cohort of participants from a large database representative
of the American population. Data was prospectively collected
and included hard outcome measures such as death and cause-
specific mortality. The presence of detailed information about
the participants allowed for adjustment for the main biologically
plausible confounders.
As for limitations, it should be noted that caffeine
consumption was evaluated by 24-h dietary recalls. It
cannot be excluded that data generated using this method
may not represent long-term dietary habits. We consider
that the inclusion of data from non-consecutive recalls to
estimate usual dietary intake distributions minimizes this
risk. Although we present additional information regarding
diet in the studied population (such as consumption of
carbohydrate, saturated fat, or fiber), no adjustment was
performed for additives present in caffeine-containing beverages.
Nonetheless, other studies showed significant association
between coffee consumption and decreased risk of death even
after adjustment for coffee additives, such as cream, milk,
sugar, or honey (32). Even though we have found a significant
association between caffeine consumption and mortality
in women with diabetes, it is possible that the differences
found are due to chance, unmeasured confounders, or the
possibility that caffeine consumers also perform other protective
behaviors, contributing to a healthy user effect. To minimize
this possibility, we have considered dietary factors and physical
activity as potential confounders. As the number of deaths
in our study was low, these estimates should be cautiously
interpreted.
In conclusion, this large observational study showed a
significant inverse association between caffeine consumption
and death from all causes in women with diabetes. These
results suggest that advising women with diabetes to drink
more caffeine may reduce their mortality. This would
represent a simple, clinically beneficial, and inexpensive
option in female patients. Further studies, ideally randomized
clinical trials, are needed to confirm this benefit. New
research should also focus on the different effects of
caffeine consumption in men and women and on the
benefits of other compounds present in caffeine-containing
beverages.
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